263 related articles for article (PubMed ID: 31858658)
1. Efficacy and tolerability on melasma of a topical cosmetic product acting on melanocytes, fibroblasts and endothelial cells: a randomized comparative trial against 4% hydroquinone.
Bronzina E; Clement A; Marie B; Fook Chong KT; Faure P; Passeron T
J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):897-903. PubMed ID: 31858658
[TBL] [Abstract][Full Text] [Related]
2. The first clinical experience on efficacy of topical flutamide on melasma compared with topical hydroquinone: a randomized clinical trial.
Adalatkhah H; Sadeghi-Bazargani H
Drug Des Devel Ther; 2015; 9():4219-25. PubMed ID: 26345129
[TBL] [Abstract][Full Text] [Related]
3. Randomized, Double-Blinded, Split-Face Study Comparing the Efficacy and Tolerability of Two Topical Products for Melasma.
Kaufman BP; Alexis AF
J Drugs Dermatol; 2020 Sep; 19(9):822-827. PubMed ID: 33026755
[TBL] [Abstract][Full Text] [Related]
4. Randomised, controlled, double-blind study of combination therapy of oral tranexamic acid and topical hydroquinone in the treatment of melasma.
Shihab N; Prihartono J; Tovar-Garza A; Agustin T; Legiawati L; Pandya AG
Australas J Dermatol; 2020 Aug; 61(3):237-242. PubMed ID: 32109318
[TBL] [Abstract][Full Text] [Related]
5. Combined use of two formulations containing diacetyl boldine, TGF-β1 biomimetic oligopeptide-68 with other hypopigmenting/exfoliating agents and sunscreen provides effective and convenient treatment for facial melasma. Either is equal to or is better than 4% hydroquinone on normal skin.
Pratchyapurit WO
J Cosmet Dermatol; 2016 Jun; 15(2):131-44. PubMed ID: 26833454
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos.
Mendoza CG; Singzon IA; Handog EB
Int J Dermatol; 2014 Nov; 53(11):1412-6. PubMed ID: 25265986
[TBL] [Abstract][Full Text] [Related]
7. Treating epidermal melasma with a 4% hydroquinone skin care system plus tretinoin cream 0.025%.
Grimes P; Watson J
Cutis; 2013 Jan; 91(1):47-54. PubMed ID: 23461059
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial of the efficacy and safety of a fixed triple combination (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) compared with hydroquinone 4% cream in Asian patients with moderate to severe melasma.
Chan R; Park KC; Lee MH; Lee ES; Chang SE; Leow YH; Tay YK; Legarda-Montinola F; Tsai RY; Tsai TH; Shek S; Kerrouche N; Thomas G; Verallo-Rowell V
Br J Dermatol; 2008 Sep; 159(3):697-703. PubMed ID: 18616780
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the therapeutic efficacy and safety of combined oral tranexamic acid and topical hydroquinone 4% treatment vs. topical hydroquinone 4% alone in melasma: a parallel-group, assessor- and analyst-blinded, randomized controlled trial with a short-term follow-up.
Lajevardi V; Ghayoumi A; Abedini R; Hosseini H; Goodarzi A; Akbari Z; Hedayat K
J Cosmet Dermatol; 2017 Jun; 16(2):235-242. PubMed ID: 27762489
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness and safety of 3% tranexamic acid cream vs. 4% hydroquinone cream for mixed-type melasma in skin of color: a double-blind, split-face, randomized controlled trial.
Yasnova N; Sirait SP; Rahmayunita G
Acta Dermatovenerol Alp Pannonica Adriat; 2024 Jun; 33(2):83-88. PubMed ID: 38918942
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a novel picosecond laser using combination of 1 064 and 595 nm on patients with melasma: A prospective, randomized, multicenter, split-face, 2% hydroquinone cream-controlled clinical trial.
Choi YJ; Nam JH; Kim JY; Min JH; Park KY; Ko EJ; Kim BJ; Kim WS
Lasers Surg Med; 2017 Dec; 49(10):899-907. PubMed ID: 28906574
[TBL] [Abstract][Full Text] [Related]
12. An efficacy study of 3 commercially available hydroquinone 4% treatments for melasma.
Grimes PE
Cutis; 2007 Dec; 80(6):497-502. PubMed ID: 18246882
[TBL] [Abstract][Full Text] [Related]
13. A comparison of triple combination cream and hydroquinone 4% cream for the treatment of moderate to severe facial melasma.
Ferreira Cestari T; Hassun K; Sittart A; de Lourdes Viegas M
J Cosmet Dermatol; 2007 Mar; 6(1):36-9. PubMed ID: 17348994
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy of cysteamine cream compared to hydroquinone in the treatment of melasma: A randomised, double-blinded trial.
Nguyen J; Remyn L; Chung IY; Honigman A; Gourani-Tehrani S; Wutami I; Wong C; Paul E; Rodrigues M
Australas J Dermatol; 2021 Feb; 62(1):e41-e46. PubMed ID: 32981068
[TBL] [Abstract][Full Text] [Related]
15. A comparative study of topical 5% cysteamine versus 4% hydroquinone in the treatment of facial melasma in women.
Lima PB; Dias JAF; Cassiano D; Esposito ACC; Bagatin E; Miot LDB; Miot HA
Int J Dermatol; 2020 Dec; 59(12):1531-1536. PubMed ID: 32864760
[TBL] [Abstract][Full Text] [Related]
16. Investigator-Blinded, Single-Center Study to Evaluate the Efficacy and Tolerability of a 4% Hydroquinone Skin Care System Plus 0.02% Tretinoin Cream in Mild-to-Moderate Melasma and Photodamage.
Rendon M; Dryer L
J Drugs Dermatol; 2016 Apr; 15(4):466-75. PubMed ID: 27050702
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial.
Lima PB; Dias JAF; Cassiano DP; Esposito ACC; Miot LDB; Bagatin E; Miot HA
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1881-1887. PubMed ID: 33988887
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of topical 5% methimazole vs 4% hydroquinone in the treatment of melasma: A randomized controlled trial.
Gheisari M; Dadkhahfar S; Olamaei E; Moghimi HR; Niknejad N; Najar Nobari N
J Cosmet Dermatol; 2020 Jan; 19(1):167-172. PubMed ID: 31102345
[TBL] [Abstract][Full Text] [Related]
19. Combination of a 755-nm picosecond laser and hydroquinone 2% cream versus hydroquinone 2% cream alone for the treatment of melasma: A randomized, split-face, and controlled trial.
Manuskiatti W; Yan C; Gulfan MCB; Techapichetvanich T; Wanitphakdeedecha R
Lasers Surg Med; 2022 Dec; 54(10):1245-1250. PubMed ID: 36345697
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a skin-lightening cream targeting melanogenesis on multiple levels to triple combination cream for melasma.
Monheit GD; Dreher F
J Drugs Dermatol; 2013 Mar; 12(3):270-4. PubMed ID: 23545908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]